Korsana Biosciences, Inc. Common Stock
KRSA
36 hedge funds and large institutions have $11.5M invested in Korsana Biosciences, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 13 closing their positions.
4.99% less ownership
Funds ownership: 53.11% → 48.12% (-5%)
22% less funds holding
Funds holding: 46 → 36 (-10)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
55% less capital invested
Capital invested by funds: $25.6M → $11.5M (-$14.1M)
69% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$15.7K |
| 2 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$6.2K |
| 3 |
Jane Street
New York
|
+$5.96K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$5.59K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$5.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$862K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$585K |
| 3 |
EP
Eversept Partners
New York
|
-$413K |
| 4 |
D.E. Shaw & Co
New York
|
-$136K |
| 5 |
Bank of New York Mellon
New York
|
-$74K |
KRSA Hedge Fund Activity: Q2 2022 in Review
36 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q2 2022, worth a combined $11.5M — down 55% from $25.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of KRSA and 4 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $15.7K. The largest seller was Pura Vida Investments, exiting entirely with an estimated $862K sold.
- 36 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q2 2022, down from 46 in Q1 2022.
- Funds reported $11.5M of Korsana Biosciences, Inc. Common Stock stock for Q2 2022, down 55% quarter-over-quarter.
- 4 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q2 2022 and 13 closed out, a net change of -9 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q2 2022 was Renaissance Technologies, an estimated $15.7K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q2 2022 was Pura Vida Investments, an estimated $862K sold.
Based on aggregated 13F filings for Q2 2022.